Welcome to our dedicated page for Lensar SEC filings (Ticker: LNSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lensar鈥檚 femtosecond laser technology may feel elegantly simple in the operating room, but its SEC disclosures are anything but. Clinical-trial milestones, FDA submissions, and revenue from single-use cataract consumables all hide inside lengthy reports that can exceed 250 pages. If you have ever asked, 鈥淗ow do I read Lensar鈥檚 annual report 10-K?鈥� or searched for 鈥淟ensar insider trading Form 4 transactions,鈥� you already know the challenge.
Stock Titan solves that problem. Our AI reviews every Lensar quarterly earnings report 10-Q filing, Form 8-K material events, and proxy statement executive compensation table the moment they hit EDGAR. In seconds you receive clear, plain-English explanations鈥�Lensar SEC filings explained simply. Need to spot Form 4 insider transactions in real time? We surface each executive stock transaction and connect it to upcoming FDA catalysts. Looking for segment margins on laser hardware versus consumables? Our AI-powered summaries highlight that too, so you can focus on decisions, not document hunts.
Whether you want a quick 鈥淟ensar earnings report filing analysis,鈥� alerts on 鈥淟ensar executive stock transactions Form 4,鈥� or a deep dive into 鈥淟ensar annual report 10-K simplified,鈥� everything is here. You鈥檒l find:
- All historical and current filings鈥�10-K, 10-Q, 8-K, S-1, Form 4鈥攗pdated in real time
- AI-generated key-point digests that translate ophthalmic-device jargon into actionable data
- Downloadable tables tracking FDA clearance language across multiple periods
Stop scrolling through PDFs; start understanding Lensar SEC documents with AI and make informed decisions faster.
Universal Display Corp. (OLED) 鈥� Form 4 filing dated 07/02/2025
Director Sidney D. Rosenblatt reported the acquisition of 342 shares of OLED common stock on 06/30/2025. The transaction is coded 鈥淎鈥� (acquisition) at a stated price of $0, implying the shares were received without cash consideration (e.g., grant or award). Following the transaction, the director鈥檚 direct ownership stands at 136,616 shares. In addition, he holds 2,830 shares indirectly via a Grantor Retained Annuity Trust and 17,499 shares through his spouse.
The purchase increases Rosenblatt鈥檚 direct stake by less than 0.3%, leaving his overall beneficial ownership essentially unchanged in percentage terms relative to Universal Display鈥檚 outstanding share count. Because of the small size and zero-dollar consideration, the filing is unlikely to be financially material, but it does reinforce continued insider alignment with shareholders.
LENSAR (NASDAQ:LNSR) filed additional proxy materials for its pending $14 per-share cash merger with Alcon. The supplement answers shareholder demand letters claiming the May 19 definitive proxy omitted material facts, potentially violating Sections 14(a)/20(a). To pre-empt litigation, LENSAR adds disclosures while denying wrongdoing.
Key additions:
- Confirms no discussions of post-merger employment or equity for executives during Feb 21-26 2025 talks.
- Updates Wells Fargo Securities comps: mean EV/2025E revenue 3.9脳, median 2.8脳; LENSAR traded at 5.2脳.
- WFS selects 4.00-5.25脳 2025E and 3.00-4.00脳 2026E revenue multiples, implying $12.27鈥�$16.51 per share versus $14.00 cash offer and $16.03 discounted amount.
- Expanded precedent-transaction table (4.0脳鈥�6.5脳 LTM revenue).
The board鈥檚 recommendation and the July 2 2025 special-meeting timetable are unchanged.
FAQ
What is the current stock price of Lensar (LNSR)?
What is the market cap of Lensar (LNSR)?
What is the primary technology used by Lensar Inc?
How does Lensar Inc generate its revenue?
What distinguishes Lensar Inc's laser system from others in the market?
What benefits does the augmented reality imaging provide?
In which markets does Lensar Inc operate?
How does Lensar Inc support surgeons in optimizing surgical outcomes?
What are the key areas of focus for Lensar Inc's product portfolio?
